Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Urology. 2017 Sep 21;111:72–77. doi: 10.1016/j.urology.2017.09.002

Figure 1.

Figure 1

Adjusted* failure-free probability, according to treatment type

* Adjusted for age, gender, comorbidity, benefit plan type, employment classification, employment status, region of residence, patient MSA, provider MSA, and treatment year.

Overall, the adjusted failure-free probabilities were high for all three treatments. Endopyelotomy had the lowest failure-free rates (logrank p<0.0001). For all three treatments, the majority of failures occurred within the first two years.